Conference - Bethesda, MD, US
A 2-day conference with record breaking attendance that covered all important aspects of immunogenicity for biotherapeutics: Assay Developments; PK/PD Case Studies; Relationship between Hypersensitivity and Immunogenicity; Immunogenicity in the Clinic, and Global Regulatory Concerns.
A few quotes about the event:
"A very comprehensive program with industry and regulators", Dan Mytych, Amgen
"It was so well organized and the topics were timely. This must be one of the best conferences on immunogenicity so far."Marie T. Rock, Ph.D., Vice President, Protein Bioanalysis, Midwest BioResearch LLC, a Wil Research Company.
Part One: Immunogenicity Assessment and Clinical Relevance October 10-11
Combined Session:
Regulatory Guidance October 11
Part Two: Immunogenicity Prediction and Mitigation October 11-12
Pre-Conference Short Courses
October 9 SC1: Assays for Measuring Binding Antibodies
SC2: Neutralizing Antibody Assays
SC3: Navigating the Regulatory Hierarchy of Concerns to Minimize the Impact of Immunogenicity-Related Risks on Product Registration (Dinner Short Course)
(Courtesy of http://www.healthtech.com/)
Tue, Oct 9, 2012 - Fri, Oct 12, 2012
DoubleTree by Hilton Hotel, 8120 Wisconsin Avenue, Bethesda, MD 20814
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows
